Molecular classification and overcoming therapy resistance for acute myeloid leukemia with adverse genetic factors
D Ikeda, SG Chi, S Uchiyama, H Nakamura… - International Journal of …, 2022 - mdpi.com
The European LeukemiaNet (ELN) criteria define the adverse genetic factors of acute
myeloid leukemia (AML). AML with adverse genetic factors uniformly shows resistance to …
myeloid leukemia (AML). AML with adverse genetic factors uniformly shows resistance to …
[HTML][HTML] The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia
Abstract Chronic Myeloid Leukemia (CML) is characterized by chromosomal aberrations
involving the fusion of the BCR and ABL genes on chromosome 22, resulting from a …
involving the fusion of the BCR and ABL genes on chromosome 22, resulting from a …
Discovery of New Imidazo[2,1-b]thiazole Derivatives as Potent Pan-RAF Inhibitors with Promising In Vitro and In Vivo Anti-melanoma Activity
BRAF is an important component of MAPK cascade. Mutation of BRAF, in particular V600E,
leads to hyperactivation of the MAPK pathway and uncontrolled cellular growth. Resistance …
leads to hyperactivation of the MAPK pathway and uncontrolled cellular growth. Resistance …
Combination Therapies with Kinase Inhibitors for Acute Myeloid Leukemia Treatment
S Takahashi - Hematology Reports, 2023 - mdpi.com
Targeting kinase activity is considered to be an attractive therapeutic strategy to overcome
acute myeloid leukemia (AML) since aberrant activation of the kinase pathway plays a …
acute myeloid leukemia (AML) since aberrant activation of the kinase pathway plays a …
Mechanisms of resistance to targeted therapies for relapsed or refractory acute myeloid leukemia
EM Kropp, Q Li - Experimental hematology, 2022 - Elsevier
Highlights•Despite advances with IDH1/2, FLT3, and BCL-2 directed therapies, treatment
resistance and relapse remain frequent•Activating RAS mutations are associated with …
resistance and relapse remain frequent•Activating RAS mutations are associated with …
Genomic landscape of hyperleukocytic acute myeloid leukemia
L Largeaud, S Bertoli, E Bérard, S Tavitian… - Blood Cancer …, 2022 - nature.com
Approximately 20% of patients with acute myeloid leukemia (AML) present at diagnosis with
hyperleukocytosis, which is commonly defined as a white blood cell count> 50× 109/L or> …
hyperleukocytosis, which is commonly defined as a white blood cell count> 50× 109/L or> …
Refining AML treatment: the role of genetics in response and resistance evaluation to new agents
Simple Summary Acute myeloid leukemia (AML) is an aggressive cancer of the
hematopoietic system. At present, we know that AML is heterogeneous and varies from one …
hematopoietic system. At present, we know that AML is heterogeneous and varies from one …
Pan-RAF Inhibition Shows Anti-Leukemic Activity in RAS-Mutant Acute Myeloid Leukemia Cells and Potentiates the Effect of Sorafenib in Cells with FLT3 Mutation
Simple Summary We demonstrate that the pan-RAF inhibitor LY3009120 induces apoptosis
and inhibits proliferation in AML cells harboring RAS or FLT3 mutations through action on …
and inhibits proliferation in AML cells harboring RAS or FLT3 mutations through action on …
Dysregulated MAPK signaling pathway in acute myeloid leukemia with RUNX1 mutations
M He, Y Jia, Y Wang, X Cai - Expert Review of Hematology, 2022 - Taylor & Francis
Background Acute myeloid leukemia (AML) is a hematologic malignancy with genetic
alterations. RUNX1, which is an essential transcription factor for hematopoiesis, is frequently …
alterations. RUNX1, which is an essential transcription factor for hematopoiesis, is frequently …
Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells
H Cho, JE Jang, JI Eom, HK Jeung, H Chung… - … Hematology & Oncology, 2021 - Springer
Background The evasion of apoptosis through dysregulated Bcl-2 family members is a
hallmark of leukaemia stem cells (LSCs) in acute myeloid leukaemia (AML). Therefore …
hallmark of leukaemia stem cells (LSCs) in acute myeloid leukaemia (AML). Therefore …